BRAF and melanoma: In melanoma, trametinib single agent increased PFS by 4–7 months in BRAF V600E mutant tumors.10 Interestingly, there was a partial response rate of 10% in BRAF wild-type tumors, demonstrating that a subset of non-BRAF mutant tumors may benefit from MAPK inhibition.